<DOC>
	<DOCNO>NCT01383941</DOCNO>
	<brief_summary>This epidemiologic , multi-center , cross-sectional study define phenotypic characteristic Difficult-to-Treat asthma , among child age 6 17 year , receive one year guidelines-based therapy asthma rhinitis/rhinosinusitis .</brief_summary>
	<brief_title>Asthma Phenotypes Inner City</brief_title>
	<detailed_description>Asthma complex , heritable disease affect 11.2 % U.S. population , represent approximately 9 million child 23 million adult . Although underlying characteristic asthma exist virtually patient , clinical expression disease response treatment highly variable . The purpose study identify characteristic discriminate Difficult-to-Treat Easy-to-Treat asthma define inner-city population adherent study-directed asthma treatment management .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Participants meet follow criterion eligible enrollment . Participants may reassess initially eligible . Participants eligible : Are male female age 617 year , inclusive , recruitment ; Have physician diagnosis asthma ; Have ≥ 2 episode shortacting betaagonist administration within past 12 month , exclusive use associate exerciseinduced symptom ; Have primary place residence locate one preselected recruitment census tract define APIC Manual Operations ; Meet pretreatment eligibility requirement study enrollment ( acceptable medical history physical examination result ) ; Have parent legal guardian willing sign write Informed Consent prior initiation study procedure ; Are willing sign assent form , age appropriate ; Have medical insurance Screening Visit . Coverage must effect Screening Enrollment order enrol . Participants meet follow criterion eligible enrollment may reassess . Participants ineligible : Have ≥ 2 lifethreatening asthma exacerbation last 2 year require intubation mechanical ventilation , result hypoxic seizure ; Are pregnant lactating . ( Females childbearing potential must remain abstinent use medically acceptable birth control method ( e.g . oral , subcutaneous , mechanical , surgical contraception ) throughout study . This safety , may difficult assess asthma control since lung function may change , make difficult interpret outcome measure ) ; Will allow study clinician manage disease duration study willing change asthma medication follow protocol ; Are unable use metereddose inhaler ( MDI ) administration betaagonist rescue medication use dry powder inhaler ( Diskus® ) administration asthma controller regimen ; Are currently receive hyposensitization therapy receive hyposensitization therapy allergen past year prior recruitment ; Are currently participate asthmarelated pharmaceutical study intervention study participate another asthmarelated pharmaceutical study intervention study month prior recruitment ; Do sleep least 4 night per week home ; Have sibling person live home enrol study ; Live foster parent ; applicable participant able provide consent ; Do access phone ( need scheduling appointment ) ; Who currently take , take follow medication within 4 week Screening Visit ( Visit 1 ) : Monoamine oxidase inhibitor ( phenelzine , tranylcypromine ) ; Tricyclic tetracyclic antidepressant ; beta adrenergic blocker drug ( oral topical ) ; Anticonvulsants ( carbamazepine , phenobarbital , phenytoin , mephobarbital , primidone , ethosuximide , methsuximide , felbamate , gabapentin , lamotrigine , levetiracetam , oxcarbazepine , tiagabine , topiramate , valproic acid , divalproex sodium , zonisamide ) ; Protease inhibitor ( ritonavir , indinavir , nelfinavir ) ; Calcium channel blocker ( verapamil , diltiazem ) ; Modafinil ; Tamoxifen ; nonnucleoside reverse transcriptase inhibitor ; Macrolide antibiotics* ( erythromycin , clarithromycin , dirithromycin , troleandomycin ) ; chloramphenicol ; nefazodone ; aprepitant ; St John 's Wort ; Rifampin* ; Azole Antifungals* ( ketoconazole , fluconazole , itraconazole ) ; Sibutramine* ; bergamottin ( constituent grapefruit juice ) ( *may rescreened therapy shortlived ) ; Should include study reason , accord investigator 's discretion . This would include , judgment investigator , clinical care participant would compromise treatment algorithm ; Are receive treatment omalizumab , omalizumab treatment within three month prior screen ; Are able perform spirometric pulmonary function test ( PFTs ) ; Are adherent controller medication Visit 1 Visit 0 ( define medication use le 50 % , ( Ref : Section 6.6 study protocol determine treatment adherence ) ; Participants meet follow criterion eligible enrollment may reassess . Participants ineligible : Do primarily speak English ( Spanish center Spanish speaking staff ) . Exclusion also apply child 's caretaker ; Plan move area study period ( 13 month ) ; Have medical illness opinion investigator would . ) increase risk subject would incur participate study ; b . ) interfere measure outcome study ; c. ) interfere performance study procedure . Examples disease : phenylketonuria , cystic fibrosis , bronchiectasis , type 1 diabetes , hemophilia , Von Willebrand disease , sickle cell disease , cerebral palsy , rheumatoid arthritis , lupus , psoriasis , hyperimmunoglobulin E syndrome , parasite infection ( ) , WiskottAldrich Syndrome allergic bronchopulmonary aspergillosis ; Have know hypersensitivity medication use treatment asthma rhinitis ; Have current , severe hypersensitivity milk ; Have current diagnosis cancer , currently investigate possible cancer , history cancer .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>asthma</keyword>
	<keyword>rhinitis</keyword>
	<keyword>difficult-to-treat asthmatic</keyword>
	<keyword>phenotype</keyword>
</DOC>